Key Points
- Director Bruce Cozadd sold 77,500 shares on Nov. 26 at an average price of $177.81, totaling $13,780,275.
- After the sale he retains 393,332 shares — a 16.46% reduction in his position valued at about $69.94 million.
- Analysts remain largely positive, with a consensus "Moderate Buy" rating and an average price target of $195.67, and several firms recently raised targets into the $205–$209 range.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the transaction, the director owned 393,332 shares of the company's stock, valued at approximately $69,938,362.92. The trade was a 16.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Jazz Pharmaceuticals Price Performance
Shares of NASDAQ JAZZ opened at $172.12 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $10.46 billion, a price-to-earnings ratio of -25.57, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99. The business has a 50 day simple moving average of $144.71 and a 200-day simple moving average of $125.74.
Analyst Ratings Changes
JAZZ has been the topic of a number of recent research reports. Morgan Stanley raised their price target on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an "overweight" rating in a research report on Monday, November 17th. Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an "outperform" rating in a report on Tuesday, November 18th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. UBS Group reiterated a "neutral" rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Finally, Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the stock an "outperform" rating in a report on Monday, November 17th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $195.67.
View Our Latest Stock Analysis on JAZZ
Hedge Funds Weigh In On Jazz Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. EverSource Wealth Advisors LLC grew its holdings in Jazz Pharmaceuticals by 9.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company's stock worth $130,000 after buying an additional 81 shares in the last quarter. Tectonic Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company's stock worth $742,000 after purchasing an additional 82 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Jazz Pharmaceuticals by 0.6% during the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company's stock valued at $1,651,000 after purchasing an additional 90 shares during the period. Fairbanks Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company's stock valued at $3,298,000 after purchasing an additional 94 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its holdings in Jazz Pharmaceuticals by 8.7% in the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company's stock worth $133,000 after purchasing an additional 100 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
